Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.

Feng WangNing ZhaoGe GaoHong-Bin DengZhi-Hui WangLi-Li DengYu YangChanglian Lu

Published in: Journal of cancer research and clinical oncology (2020)

TP53 MUT is a poor prognostic factor in LUAD patients, and the prognosis of TP53/EGFR co-mutation is worse. GPC3, CCL28, GPR37, and NPY may be novel prognostic markers and potential therapeutic targets for patients with dual TP53/EGFR mutation LUAD.

Keyphrases

prognostic factors
small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
end stage renal disease
newly diagnosed
chronic kidney disease
fatty acid
climate change